August 7th, 2014 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal …
Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
Single, Lowest Dose Group of ALN-AT3 Achieves Statistically Significant Knockdown of AT and Increase in Thrombin Generation in “Part A” of Phase 1 Study in …